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QUANTITATIVE COAGULASE AND TOXIN PRODUCTION
BY STAPHYLOCOCCI IN RELATION TO THE CLINICAL
SOURCE OF THE ORGANISMS*
M. TAGER AND H. B. HALES
Recent studies have reopened the problem of the relation of
coagulase production to staphylococcal infection.3 Although the in
vivo significance of this substance is controversial, there is very little
question that the capacity of staphylococci to clot plasma in vitro serves
as a useful index of pathogenicity. The test is usually carried out by
inoculating rabbit or human plasma with a young, living culture.
Coagulation of the plasma within 24 hours is regarded as positive.
However, since the organisms continue to multiply during the incuba-
tion period, this procedure does not afford an accurate index of the
quantity of coagulase formed by the strain. On the other hand, titration
of suitable bacteria-free preparations under standard conditions might
serve to indicate the quantitative limits of coagulase production by the
staphylococci. Although it was at first asserted that living organisms
were essential for the demonstration of coagulase, the studies of
Walston"3 and of others' 7, 8 clearly proved that bacteria-free prepara-
tions might possess activity. No systematic studies, however, are extant
to define the range of activity possessed by different strains. It therefore
seemed desirable to determine the degree to which strains vary in their
capacity to elaborate coagulase in vitro, and to note whether this prop-
erty correlates with toxin production and with the clinical sources from
which the strains have been derived.
Materialsandmethods
The staphylococci. The strains were obtained from patients at the
New Haven Hospital,t and were first grown on blood agar plates.
Colonies exhibiting the gross morphological characteristics of hemolytic
* From the Department of Bacteriology, Yale University School of Medicine. Aided
by a grant from the Navy Department, Office of Naval Research, and from the Fluid
Research Fund of Yale University School of Medicine.
t The cultures were kindly made available by Mrs. Mildred Fousek of the Department
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Staphylococcus aureus or hemolytic Staphylococcus albus were picked,
subinoculated on extract agar slants, and then subjected to a preliminary
screening by the standard coagulase test with living cultures and by
mannite fermentation tests. Only strains positive by these procedures
were used for further quantitative studies. The clinical sources were
arbitrarily grouped into 6 categories (table 2). The nose and throat
strains, obtained, in the main, from the Pediatrics Service, presumably
were notproducing any clinical effects ascribable to them. The relation-
ship of the staphylococci derived from the ears, eyes, skin, and vagina,
as well as those from urine, to the production of clinical disease, is
perhaps intermediate, in the sense that at times the organisms were
incriminated as the causative organisms, while at other times they were
secondary invaders or even played no special pathogenic r6le. The
strains assembledundergroup 6 weremostlikelydirectly involved in the
production of lesions. In this group are included strains from boils,
carbuncles, sepsis, osteomyelitis, staphylococcal endocarditis, infected
burns, infectedsurgicalwounds, etc.
The production of coagulase. Difco brain-heart infusion broth was
employed, made up to contain 37 gm. per 1000 ml. of distilled water.
To this was added a mixture of trace elements, in the amount of 1 ml.
per liter, and of the following composition:
gm.per liter parts per million of gin. perliterelement in medium
Boric acid 0.06 0.01
MnCl2.4HOH 0.035 0.01
CuSO4.5HOH 0.04 0.01
Molybdic acid 0.02 0.01
FeCl3.6HOH 0.25 0.05
ZnSO4 0.2 0.07
KI 0.1 0.025
The staphylococci were seeded from extract agar slants into tubes
of brain-heart broth, incubated for 3 hours at 370C., and 3 ml. lots
were subinoculated into 20 to 30 ml. of the same medium in bottles
4 x 4x 10 cm. in size, and of a capacity of 100 ml. The cultures were
then incubated for 5 days at 35 to 37'C. At this time, the broth was
cleared by centrifugation, and merthiolate was added to a final con-
centration of 1:10,000. No filtration was carried out, but controls
established that the coagulase titers represented the content of the
supernatant fluid rather than the further elaboration of coagulase by
the organisms.
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Titration of coagulase. Beginning with a 1:10 dilution, serial
doubling dilutions were carried out in a total volume of 0.5 ml. of a
solution of 2 per cent peptone-saline containing 1:5000 merthiolate. A
separate pipette was used for each dilution. To each tube, 0.5 ml. of
citrated human plasma were added. Readings were taken at 37°C. at
intervals during the first hour and at 24 hours. The titer of coagulase
was taken as the least amount showing a clot at 24 hours; anything less
than a "1 plus" being disregarded. To assure adequacy of the test
conditions, a known strain possessing high coagulase activity was in-
cluded for titration with each group of strains being tested.
Standardization of plasma. Citrated human plasma was used, con-
taining 10 per cent by volume of the anticoagulant. This plasma,*
out-dated for transfusion purposes, or otherwise unsuited for clinical
use, was kept at 4°C. for from 1 to 21 days, and when released from
the Blood Bank was preserved in a deep-freeze unit at -15 to -20°C.
A "standard" coagulase solution was maintained, and since it was stable,
new plasmas were always first checked against it. A "satisfactory"
plasma clotted with the standard coagulase diluted 1:5120. If the
plasma under investigation failed to coagulate at this dilution of the
standard coagulase solution, corrections were made accordingly when
it was used for the titration of the unknown preparations of coagulase.
Thus, if the plasma clotted the standard coagulase at 1:2560, the titer
of the unknown coagulase sample was corrected by multiplying by two.
Plasmas were seldom used if they required more than a 100 per cent
correction.
Produiction of rahbit, sheep, and human red blood cell lysins. The
method has been previously described.10 In brief, the toxins were pro-
duced in a rapid shake culture for 16 hours, using heart infusion broth.
The titration of the toxins was according to well-established procedure.14
The Lh dose of the rabbit cell lysin was determined against an antitoxin
prepared from a therapeutic Lederle staphylococcal antitoxin, which, in
turn,hadbeen adjustedagainsttheNationalInstituteofHealthstandard.
With each group of unknown strains, a culture of "Wood 46," a good
alpha hemolysin-producing organism, was included to serve as a check
of the adequacy of the test conditions.
The authors are indebted to Miss Juliet Drabkin of the Blood Bank of New Haven
Hospital for making the plasma available.
43YALE JOURNAL OF BIOLOGY AND MEDICINE
Experimentalresults
The quantitative production of coagulase. The distribution of
coagulase titers among 242 positive strains is given in table 1. The
organisms were classified as "low," "intermediate," and "high" in
coagulase production according to the arbitrary division indicated in the
table. It will be noted that the majority of the strains exhibit a capacity
to elaborate a limited amount of coagulase in vitro, although a small
group possesses this property to a high degree.
TABLE 1
PRODUCTION OF COAGULASE BY STAPHYLOCOCCI
Coagulase tWter Per cent of staphylococcus strains
Low
Living cultures only 47.5
1:20 2.5
1:40 8.9
1:80 7.2
66.1 Total
Intermediate
1:160 9.7
1:320 7.0
1:640 8.5
25.2 Total
High
1:1280 4.1
1:2560 3.0
1:5120 0.8
1:10,240 o.4
1:20,480 0.4
8.7 Total
The strains were thengrouped according to the clinical sources from
which they were derived (table 2).
So,
1.
2.
3.
4.
5.
6.
TABLE 2
COAGULASE TITERS AND THE CIUNICAL SOURCE OF STAPHYLOCOCCI
urce Low Intermediate High ToWta
Nose 56 19 12 87
Throat 9 6 2 17
Ears 5 3 1 9
Eyes, skin, vagina 24 8 4 36
Urine 8 5 0 13
Boils, osteomyelitis, etc. 58 20 2 80
61 21 242
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It appeared of particular interest to determine whether the results
obtained with the group most intimately associated with the production
of clinical disease, group 6, differed significantly from the other sources.
Subjecting the data to the chi-square test* it was first found that differ-
ences among the first four groups were not valid. Similarly, group 4 did
notdiffersignificantly fromgroup 6. When, however, thefirsttwo or the
first four groups were compared to group 6, the difference was statis-
tically valid, with P giving a value of 0.03.
The question might well be raised as to the validity of the methods
used. In thecourse ofobservations onmany factors influencing coagulase
production, it was established that duplicate checks on samples grown
in separate bottles may be readily obtained when tests are carried out at
the same time, with the same inoculum, and on the same medium. Such
differences as may occur usually fall within less than one dilution, and
identical results were frequently achieved. It was further desirable to
note the constancy of coagulase production by the same strain at
different times. Accordingly, 100 strains were selected at random and
retested some months later under as nearly identical conditions as
possible. That the titers were frequently not the same as previously ob-
tained is not surprising. However, 90 per cent of the organisms showed
titers within the same general group of "low," "intermediate," or "high"
as on the previous test, while 10 per cent of the strains exhibited greater
disparity in the results. It should be pointed out, however, that under
prolonged cultivation a strain may undergo profound changes in its
capacity to produce coagulase.
The quantitative production of rabbit cell lysin. In all, 235 strains
were examined for alpha lysin, and the titers were expressed in terms
of the Lh dose of the toxin. The results are summarized in table 3, in
which the strains were arbitrarily grouped under the headings of "low,"
"intermediate," and "high" as indicated. It will be noted that, contrary
to the preponderance of low coagulase production, toxin elaboration
was equally distributed among the three categories.
TABLE 3
PRODUCTION OF RABBIT CELL LYSIN BY STAPHYLOCOCCI
Lb titer Per cent of staph. straism
Low (1.0, 0.75, 0.5, 0.25 ml.) 32.3
Intermediate (0.188, 0.125, 0.09 ml.) 34.9
High (0.06, 0.04, 0.03, 0.02, 0.01 ml.) 32.7
* The authors are indebted to Dr. John H. Watkins for assistance in the statistical
evaluation of the data.
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The strains were then classified under the same clinical categories
as for the coagulase titers (table 4).
TABLE 4
CLINICAL SOURCE OF STAPHYLOCOCCI AND ALPHA HEMOLYSIN
Source Low Intermediate High Total
1. Nose 26 27 32 85
2. Throat 5 4 8 17
3. Ears 5 2 2 9
4. Eyes, skin, vagin. 11 15 6 32
5. Urine 2 5 6 13
6. Boils, osteomyelitis, etc. 27 29 23 79
Totals: 76 82 77 235
When the strains derived from the mucous membranes of groups
1,2, and 3 weresetupagainstgroup 6 in achi-square test, no statistically
significant difference was evident, with P giving a value of 0.6.
The relation of coagulase titers to Lh values. Coagulase titers and
Lh levels of toxin were determined in 230 strains from the standpoint
of a possible correlation between these two properties. This was
carried out by plotting the logarithm of the coagulase titers against the
logarithm of the Lh values. It was readily apparent that no correlation
existed and that the level of the two products varied independently.
Hot-cold sheep lysin and human red blood cell lysin. From the
coagulase-positive staphylococci, 83 strains were chosen at random,
and hot-cold sheep lysin and the hemolysis of human red blood cells
were determined. Since in neither instance are standard antisera avail-
able, the activity was expressed in terms of the end-point of hemolysis.
All coagulase-positive strains examined exhibited some lysin toward
sheep cells at 370C. However, only those strains showing a significant
increase in lytic activity on refrigeration were interpreted as positive. In
all, only 15 strains, or 18 per cent of the 83 strains, elaborated hot-cold
sheep cell lysin (table 5).
In general, the capacity to lyse human cells was of a lower order
of activity than was the ability to lyse rabbit cells. No titers above
1:640 were encountered, and 5 of 79 coagulase- and alpha-lysin-
positive strains failed completely to act on human red blood cells. The
occurrence of human cell lysin is indicated in table 6.
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TABLE 5
POSITIVE SHEEP CELL LYSIN BY STAPHYLOCOCCI
Source
Nose
Nose
Nose
Nose
Nose
Throat
Throat
Eye
Skin
Skin
Skin
Empyema
Inf. burn
Boil
Pus
Sheep-cell lysin
80-5120*
320-5120
160-2560
160-2560
320-1280
160-2560
320-5120
320-5120
40-5120
320-5120
320-5120
320-5120
40-5120
40-5120
160-640
Lb rabbit lysin
0.06
0.09
0.06
0.09
0.09
0.047
0.047
0.188
0.25
0.09
0.06
0.09
0.188
0.375
0.25
Haman lyuin
640
160
160
320
160
160
80
40
40
160
160
80
160
80
160
Coagulase
10
10
80
10
10
160
20
10
10
20
10
40
10
1280
160
* The first number indicates the titer at 370 C. at 1 hour; the second, the hemolytic
end-point after refrigeration overnight.
TABLE 6
CUNICAL SOURCE OF STAPHYLOCOCCI AND HUMAN CELL LYSIN
Source Low (0 to 1:80) Interm. (1:160 to 1:640) Higb Total
1M NMse- thrrnat 11 n UA L. X VOIF.; LIlVVaL
2. Eyes, skin, vagina
3. Boils, osteo., etc.
16
22
Totals 61
I 1
2
5
18
v rz
0 18
0 27
79
Thedifference between the nose and throat strains and those derived
from lesions (group 3) was not statistically valid.
Discussion
It seems evident from the present studies that the quantitative
elaboration of coagulase and of several of the staphylococcal toxins in
vitro cannot serve as a yardstick for the evaluation of the risk of the
infection to the patient. Thus, staphylococcal sepsis or other severe
systemic disease may be associated with a strain endowed with high,
intermediate, or low toxigenic power and coagulase activity. It appears
to be sufficient that the organism under consideration is coagulase
positive and is able toproduce toxins, and neither need high titers arouse
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undue alarm, nor should low in vitro activity lull one into a false sense
of security with regard to the potentialities of the staphylococcal in-
fection. Two fatal cases in the present series, osteomyelitis and endo-
carditis, yielded organisms producing low to intermediate amounts
ofcoagulase and toxin.
The difference in coagulase production between the strains isolated
from the nose and throat and those from lesions of group 6 (table 2)
is not readily explained. Possibly, not too much importance should be
attached to this, since the chi-square test failed,to place the difference in
the "highlysignificant" category. Hale and Smith3 have recently brought
forward evidence suggesting that coagulase may interfere with the
in vivo phagocytosis of the organism. Therefore, strains exhibiting
higher activity in vivo might have greater survival powers, and might
maintain themselves more effectively on such mucous membranes as
the nose and throat. Furthermore, from these sites, the organisms may
gain access to other parts of the body and thus serve as endogenous foci
for systemic invasion.2' " It may also be that the many other factors
which come into play in the reaction between the host and the invading
staphylococcus modify the capacity of the organism to elaborate
coagulase. A further possibility is that the substrate provided by the
host at one particular area favors the selection of strains of different
coagulase-producing powers. Studies, not germane to the present dis-
cussion, have indicated that a given strain may give rise to daughter
strains significantly differing in their capacity to elaborate coagulase.
Although the role of the toxins in staphylococcal infection needs
far greater clarification,'l 12 recent work has stressed specific clinical
manifestations which may point to the presence of intoxication."X 4'5
Awareness of these clinical guide-posts, in the face of infection not
responding satisfactorily to penicillin or to sulfonamide therapy, may
prove of far greater service to the physician than the attempts at direct
application of quantitatively established coagulase and toxin titers to
the appraisal of the clinical picture.
Summary
1. The quantitative production of coagulase and of toxins has been
studied in an attempt to determine the correlation of these properties
with the clinical origin of the staphylococci.
2. Of 242 strains, 66 per cent produced slight amounts of coagulase
while 8.7 per cent yielded high titers.
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3. More strains derived from the nose, throat, ears, eyes, skin, and
vagina had higher coagulase titers than did strains isolated from
lesions, and this difference was statistically significant.
4. No significant differences were found in the quantity of rabbit
cell lysin and sheep and human cell lysins among strains derived from
different clinical sources.
5. There was no correlation between the quantity of coagulase and
of rabbit cell lysin production.
6. The possible clinical implications of the findings are considered.
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